v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 285,053 $ 322,399
Accounts receivable, net 28,493 38,520
Inventory 49,773 50,082
Prepaid expenses and other current assets 12,963 16,770
Interest rate cap 0 1,375
Total current assets 376,282 429,146
Property and equipment, net 166,428 164,474
Goodwill 159,878 159,878
Intangible assets, net 199,581 194,957
Other assets 57,582 59,789
Total assets 959,751 1,008,244
Current liabilities:    
Accounts payable 9,525 11,957
Accrued expenses and other current liabilities 44,603 36,407
Deferred revenue 2,756 2,375
Current portion of long-term debt 5,440 5,440
Current portion of finance lease liabilities 834 792
Total current liabilities 63,158 56,971
Long-term debt, less current portion 289,499 290,492
Finance lease liabilities, less current portion 30,881 31,106
Deferred tax liabilities 1,974 11
Other long-term liabilities 43,966 52,455
Total liabilities 429,478 431,035
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Additional paid-in capital 186,797 181,874
Retained earnings 110,946 140,891
Accumulated other comprehensive income 324 0
Total stockholders’ equity attributable to Maravai LifeSciences Holdings, Inc. 300,614 325,292
Non-controlling interest 229,659 251,917
Total stockholders’ equity 530,273 577,209
Total liabilities and stockholders’ equity 959,751 1,008,244
Class A Common Stock    
Stockholders’ equity:    
Common stock 1,440 1,420
Class B Common Stock    
Stockholders’ equity:    
Common stock $ 1,107 $ 1,107

Source

HTML PDF
ZIP